Rao Prabhala, William E Pierceall, Mehmet Samur, Lakshmi B Potluri, Kevin Hong, Teresa Peluso, Srikanth Talluri, Angela Wang, Aishwarya Katiki, Sahan D Vangala, Michael Buonopane, Vaishnavi Bade, Hannah Seah, Arthur Krogman, Sanika Derebail, Mariateresa Fulciniti, Suzan B Lazo, Paul Richardson, Kenneth Anderson, Jill Corre, Herve Avet-Loiseau, Anjan Thakurta, Nikhil Munshi
BACKGROUND: Multiple Myeloma (MM) patients exhibit dysregulated immune system, which is further weakened by chemotherapeutic agents. While cereblon-modulating agents, such as pomalidomide and lenalidomide, have been found to improve the immune profile, the efficacy of their impact in combination with other treatments is yet unknown. METHODS: We conducted an immune-profiling of a longitudinal cohort of 366 peripheral blood samples from the CC4047-MM-007 (OPTIMISMM, NCT01734928) study...
2023: Frontiers in Oncology